Table S1. Cohort of B-ALL patients and controls used in the study

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient #** | **Type** | **Age at diagnosis** | **% blasts at diagnosis** | **Sample ID** | **Sample Remission** | **Sample Relapse** | **Analysis** |
| S1 | common ALL | 2 | 72 | NMFZ-01 | NMFZ-21  NMFZ-R15 |  | DS  RS |
| S2 | common ALL | 9 | 45 | NMFZ-02  NMFZ-R11 | NMFZ-R10 |  | DS  RS |
| S3 | pre-B-ALL | 3 | 88 | NMFZ-03 | NMFZ-33 |  | DS |
| S4 | common ALL | 1 | 63 | NMFZ-04 | NMFZ-34  NMFZ-R21 |  | DS  RS |
| S5 | common ALL | 3 | 63 | NMFZ-05 | NMFZ-20 |  | DS |
| S6 | pre-B-ALL | 3 | 89 | NMFZ-06 |  |  | DS |
| S7 | pro-B-ALL | 4 months | 85 | NMFZ-07 | NMFZ-17 |  | DS |
| S8 | pre-B-ALL | 8 | 88 | NMFZ-08 |  |  | DS |
| S9 | common ALL | 15 | 65 | NMFZ-09 | NMFZ-16 |  | DS |
| S10 | pre-B-ALL | 7 months | 62 | NMFZ-10 |  |  | DS |
| S11 | common ALL | 5 | 61 | NMFZ-11 | NMFZ-14 |  | DS |
| S12 | pre-B-ALL | 4 | 84 | NMFZ-12 | NMFZ-13 |  | DS |
| S13 | common ALL | 16 | 87 | NMFZ-29 | NMFZ-15 |  | DS |
| S14 | common ALL | 11 | 30 | NMFZ-30 | NMFZ-18 |  | DS |
| S15 | common ALL | 4 | 82 | NMFZ-31 | NMFZ-19 |  | DS |
| S16 | common ALL | 7 | 89 | NMFZ-23  NMFZ-R09 | NMFZ-48  NMFZ-R08 |  | DS  RS |
| S17 | pre-B-ALL | 10 | 29 | NMFZ-24 | NMFZ-25 | NMFZ-R25, -R26 | DS  RS |
| S18 | common ALL | 2 | 83 | NMFZ-26  NMFZ-R28 | NMFZ-27  NMFZ-R29 |  | DS  RS |
| S19 | common ALL | 3 | 35 | NMFZ-35 | NMFZ-49 |  | DS |
| S20 | pre-B-ALL | 4 | 83 | NMFZ-42 | NMFZ-R46 |  | DS  RS |
| S21 | common ALL | 3 | 81 | NMFZ-R22 | NMFZ-R23, -R24 |  | RS |
| S22 | common ALL | 6 | 96 | NMFZ-R12 |  |  | RS |
| S23 | common ALL | 5 | 52 | NMFZ-R27 |  |  | RS |
| S24 | pre-B-ALL | 5 | 80 | NMFZ-R41  F369 |  |  | RS  QR |
| S25 | pre-B-ALL | 1 | 92 |  | NMFZ-R16, -R17 |  | RS |
| S26 | pre-B-ALL | 15 | 85 |  | NMFZ-R31 |  | RS |
| S27 | common ALL | 10 | 90 | F300 |  |  | QR |
|  |  |  |  |  | NMFZ-R37 |  | RS |
| S28 | common ALL | 2 | 57 | F340 |  |  | QR |
|  |  |  |  |  | NMFZ-R39, -R40 |  | RS |
| S29 | common ALL | 7 | 94 | F342 |  |  | QR |
|  |  |  |  |  | NMFZ-R03, -R05 |  | RS |
| S30 | common ALL | 4 | 90 | F500 |  |  | QR |
| S31 | common ALL | 2 | 59 | F404 |  |  | QR |
| S32 | common ALL | 5 | 74 | F461 |  |  | QR |
| S33 | common ALL | 5 | 85 | F450 |  |  | QR |
| S34 | common ALL | 4 | 70 | F438 |  |  | QR |
| S35 | common ALL | 4 | 90 | F527 |  |  | QR |
| S36 | common ALL | 5 | 95 | F554 |  |  | QR |
| C1 | control | 11 months | - | NMFZ-36 |  |  | DS |
| C2 | control | 16 | - | NMFZ-38 |  |  | DS |
| C3 | control | 8 | - | NMFZ-39 |  |  | DS |
| C4 | control | adult | - | NMFZ-R02 |  |  | RS |
| C5 | control | adult | - | NMFZ-R45 |  |  | RS |
| C6 | control | 3 months | - | F411 |  |  | QR |
| C7 | control | 17 | - | F516 |  |  | QR |
| C8 | control | 4 months | - | F335 |  |  | QR |
| C9 | control | 9 months | - | F301 |  |  | QR |
| C10 | control | 7 months | - | F291 |  |  | QR |
| C11 | control | 11 | - | F283 |  |  | QR |

ID: Initial Diagnosis; DS: Deep Sequencing; RS: Targeted RNA sequencing; QR: qRT-PCR

The Total number of B-ALL patients in this study is 36. Of them, 20 and 16 patients were analyzed by DNA or RNA sequencing, respectively, 11 by qRT-PCR. From 18 patients, both samples from initial diagnosis and from remission were available and analyzed by DNA- or RNA-sequencing or both.